Breaking Finance News

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been upgraded to Buy in a statement by BidaskClub earlier today.

BidaskClub has upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to Buy in a statement released on 7/5/2017.

On 7/04/2017, Vetr Inc. released a statement on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) upped the target price from $0.00 to $32.27 that suggested a downside of -0.03%.

Having a price of $33.31, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) traded 1.17% higher on the day. With the last stock price up -44.15% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. Teva Pharmaceutical Industries Ltd (ADR) has recorded a 50-day average of $27.46 and a two hundred day average of $30.98. Volume of trade was down over the average, with 9,162,890 shares of TEVA changing hands under the typical 14,858,400

Performance Chart

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

With a total market value of $0, Teva Pharmaceutical Industries Ltd (ADR) has with a one year low of $16.81 and a one year high of $53.96 .

A total of 22 analysts have released a report on Teva Pharmaceutical Industries Ltd (ADR). Ten analysts rating the company a strong buy, nine analysts rating the company a buy, six analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $72.82.

More About Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.